BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026

PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia from PROPEL 3 will be shared at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, taking place in Marseille, France on September 8-10, 2026.

GlobeNewsWire • Sep 2, 2026

BridgeBio to Participate in September Investor Conferences

PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:

GlobeNewsWire • Sep 1, 2026

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.

Zacks Investment Research • Sep 1, 2026

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

Zacks Investment Research • Sep 1, 2026

BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

- This voluntary agreement expands access for Medicaid patients to BridgeBio's currently marketed medicine and lowers drug costs for Americans without jeopardizing innovation and sustainability in rare diseases

GlobeNewsWire • Aug 31, 2026

Trump Administration Reaches Drug Pricing Deals With 9 Companies

The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said

WSJ • Aug 31, 2026

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM

- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging,  with up to half of patients showing clinically meaningful improvement in cardiac function in the completer analysis - Patients treated with acoramidis were observed to have an unprecedented 65 additional days alive and out of the hospital by Month 36 versus baseline placebo patients - Acoramidis demonstrated long-term efficacy and safety through 54 months across variant ATTR-CM subgroups, including p.Val142Ile and non-p.Val142Ile. These findings were simultaneously published in the European Journal of Heart Failure PALO ALTO, Calif.

GlobeNewsWire • Aug 30, 2026

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with evidence of amyloid regression in a subset of patients

GlobeNewsWire • Aug 26, 2026

BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum

BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.

Zacks Investment Research • Aug 25, 2026

Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue

BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.

Zacks Investment Research • Aug 25, 2026